What are the diagnostic criteria for hospital‑acquired pneumonia and the recommended first‑line antibiotic regimen?

Hospital-Acquired Pneumonia: Diagnostic Criteria and Antibiotic Selection

Hospital-acquired pneumonia is defined as radiologically confirmed pneumonia occurring ≥48 hours after hospitalization in non-intubated patients, and empiric antibiotic selection should be stratified by mortality risk and MRSA risk factors according to the 2016 IDSA/ATS guidelines. 1

Diagnostic Criteria

HAP requires both clinical and radiological confirmation:

• Pneumonia developing ≥48 hours after hospital admission in patients not mechanically ventilated 2
• New or progressive infiltrate on chest radiograph at the time of clinical suspicion 2
• Clinical signs of infection including fever, leukocytosis, purulent respiratory secretions 2

Important caveat: Studies show that up to 35% of clinically diagnosed HAP cases lack radiological confirmation when objective criteria are applied, representing diagnostic overuse in ward-level practice 2. Radiologically confirmed HAP is associated with higher inflammatory markers and represents a distinct clinical phenotype 2.

Obtain lower respiratory tract samples (sputum culture or other respiratory specimens) before initiating antibiotics to guide subsequent therapy narrowing 1, 3. However, do not delay empiric treatment while awaiting samples 1.

Antibiotic Selection Algorithm

Step 1: Assess Mortality Risk

High mortality risk factors include: 1

• Need for ventilatory support due to pneumonia
• Septic shock

Step 2: Assess MRSA Risk Factors

MRSA coverage is indicated when: 1

• IV antibiotic use within prior 90 days
• Unit MRSA prevalence >20% (or unknown prevalence)
• Prior MRSA colonization or infection

Step 3: Select Empiric Regimen Based on Risk Stratification

Low Mortality Risk + No MRSA Risk Factors

Choose ONE of the following: 1

• Piperacillin-tazobactam 4.5 g IV q6h (preferred based on efficacy data) 4
• Cefepime 2 g IV q8h
• Levofloxacin 750 mg IV daily
• Imipenem 500 mg IV q6h
• Meropenem 1 g IV q8h

Rationale: Network meta-analysis shows piperacillin-tazobactam may be among the most effective in reducing treatment failure (RR 0.65 vs cephalosporins) 4. These agents provide MSSA coverage, which is essential for all empiric HAP regimens 1.

Low Mortality Risk + MRSA Risk Factors Present

Choose ONE antipseudomonal agent PLUS vancomycin or linezolid: 1

Antipseudomonal options (choose one):

• Piperacillin-tazobactam 4.5 g IV q6h
• Cefepime or ceftazidime 2 g IV q8h
• Levofloxacin 750 mg IV daily
• Ciprofloxacin 400 mg IV q8h
• Imipenem 500 mg IV q6h
• Meropenem 1 g IV q8h
• Aztreonam 2 g IV q8h

PLUS one MRSA agent:

• Vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL; consider loading dose 25-30 mg/kg for severe illness) 1
• Linezolid 600 mg IV q12h 1

High Mortality Risk OR Recent IV Antibiotics (within 90 days)

Use combination therapy with TWO antipseudomonal agents (avoid combining two β-lactams) PLUS MRSA coverage: 1

Choose TWO from different classes:

• Piperacillin-tazobactam 4.5 g IV q6h
• Cefepime or ceftazidime 2 g IV q8h
• Levofloxacin 750 mg IV daily OR Ciprofloxacin 400 mg IV q8h
• Imipenem 500 mg IV q6h OR Meropenem 1 g IV q8h
• Aminoglycoside: Amikacin 15-20 mg/kg IV daily, Gentamicin 5-7 mg/kg IV daily, or Tobramycin 5-7 mg/kg IV daily
• Aztreonam 2 g IV q8h

PLUS MRSA coverage:

• Vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL) 1
• OR Linezolid 600 mg IV q12h 1

Critical note: Two antipseudomonal agents are specifically recommended for patients with structural lung disease (bronchiectasis, cystic fibrosis) or when Gram stain shows predominant gram-negative bacilli 1.

Special Considerations

Microbiological patterns from confirmed HAP: 2

• Gram-negative bacilli predominate (65% of positive cultures)
• Most gram-negatives are resistant to co-amoxiclav but susceptible to ciprofloxacin, piperacillin-tazobactam, and carbapenems
• S. aureus accounts for 35% of isolates, with most being methicillin-susceptible (83%)
• All S. aureus isolates susceptible to doxycycline

De-escalation strategy: 1, 3

• Narrow therapy based on culture results at day 3
• If MRSA coverage was empirically started but cultures are negative, discontinue anti-MRSA agents
• For proven MSSA, switch to oxacillin, nafcillin, or cefazolin (though these are not used empirically) 1
• Duration: 7 days for most patients, including those with glucose non-fermenting gram-negatives 5, 6

Penicillin allergy: If using aztreonam as sole β-lactam, ensure MSSA coverage is included separately 1.

Local antibiogram: Base all empiric decisions on unit-specific resistance patterns, ideally with HAP-specific data 1. The 20% MRSA threshold and 90% gram-negative susceptibility thresholds can be adjusted based on local institutional values 1, 3.